Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.
Novel therapeutic strategies for recurrent SCLC / Moliner, Laura; Zhang, Bingnan; Lamberti, Giuseppe; Ardizzoni, Andrea; Byers, Lauren A.; Califano, Raffaele. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 186:(2023), pp. 104017.1-104017.9. [10.1016/j.critrevonc.2023.104017]
Novel therapeutic strategies for recurrent SCLC
Lamberti, Giuseppe;Ardizzoni, Andrea;
2023
Abstract
Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
